SCHEMBL3240144

SCHEMBL3240144

CC(C)C(=O)n1ccc(N)nc1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.37
FGFR1 P11362 2/20 0.35
LMNA P02545 3/20 0.35
THRB P10828 1/20 0.35
MTOR P42345 1/20 0.35
MDM2 Q00987 1/20 0.35
NCOA1 Q15788 1/20 0.35
NCOA3 Q9Y6Q9 1/20 0.35
SLC22A6 Q4U2R8 1/20 0.35
XIAP P98170 1/20 0.34
BIRC2 Q13490 1/20 0.34
PDE3A Q14432 3/20 0.33
MAPT P10636 3/20 0.33
CACNA1F O60840 2/20 0.33
ALB P02768 2/20 0.33
CACNA1D Q01668 2/20 0.33
CACNA1S Q13698 2/20 0.33
CACNA1C Q13936 2/20 0.33
PDE4D Q08499 1/20 0.33
SLC29A1 Q99808 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27723182 0.87 XIAP (0.36) FGFR1LMNATHRBMTORMDM2
SCHEMBL3460189 0.83 LMNA (0.36) FGFR1LMNATHRBMTORMDM2
SCHEMBL21186 0.80 NOTUM (0.43) FGFR1LMNATHRBMTORMDM2
SCHEMBL17372497 0.80 PDE3A (0.34) FGFR1LMNATHRBMTORMDM2
SCHEMBL20801121 0.79 FGFR1 (0.37) FGFR1LMNATHRBMTORMDM2
Methane SCHEMBL27916787 0.79 NOTUM (0.42) FGFR1LMNATHRBMTORMDM2
SCHEMBL10679054 0.78 LMNA (0.38) FGFR1LMNATHRBMTORMDM2
SCHEMBL27819780 0.78 PARP1 (0.43) FGFR1LMNATHRBMTORMDM2
SCHEMBL27740855 0.77 NOTUM (0.41) FGFR1LMNATHRBMTORMDM2
SCHEMBL22538799 0.76 FGFR1 (0.34) FGFR1LMNATHRBMTORMDM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0934330-A1 BASE-PROTECTED NUCLEOTIDE ANALOGS WITH PROTECTED THIOL GROUPS Hanna, Michelle M. (US) 1999-08-11 EP claimed
WO-1998003532-A9 BASE-PROTECTED NUCLEOTIDE ANALOGS WITH PROTECTED THIOL GROUPS 1998-05-28 WO claimed
WO-1998003532-A1 BASE-PROTECTED NUCLEOTIDE ANALOGS WITH PROTECTED THIOL GROUPS HANNA MICHELLE M (US) 1998-01-29 WO claimed
WO-1994001445-A1 BASE-PROTECTED NUCLEOTIDE ANALOGS WITH PROTECTED THIOL GROUPS RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1994-01-20 WO claimed
EP-3643706-B1 MODIFIED NUCLEIC ACID MONOMERS AND OLIGONUCLEIC ACID ANALOGUES, WITH HIGH BIOLOGICAL STABILITY AND TARGET GENE SILENCING ACTIVITY, FOR USE IN THERAPY AND DIAGNOSIS OF CANCER AND VIRAL DISEASES EISAI R&D MAN CO LTD (JP) 2023-11-15 EP disclosed
CN-112480197-B Method for synthesizing cytosine nucleoside 新乡拓新药业股份有限公司 2022-03-08 CN disclosed
US-11208429-B2 Modified nucleic acid monomer compound and oligonucleic acid analog EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-12-28 US disclosed
CN-112480197-A Method for synthesizing cytosine nucleoside 新乡拓新药业股份有限公司 2021-03-12 CN disclosed
EP-3643706-A9 MODIFIED NUCLEIC ACID MONOMER COMPOUND AND OLIGONUCLEIC ACID ANALOG Eisai R&D Management Co., Ltd. (JP) 2020-09-23 EP disclosed
CN-108409818-B Method for synthesizing cytosine nucleoside 新乡拓新药业股份有限公司 2020-09-11 CN disclosed
US-20200216488-A1 MODIFIED NUCLEIC ACID MONOMER COMPOUND AND OLIGONUCLEIC ACID ANALOG EISAI R&D MANAGEMENT CO., LTD. (JP) 2020-07-09 US disclosed
EP-3643706-A1 MODIFIED NUCLEIC ACID MONOMER COMPOUND AND OLIGONUCLEIC ACID ANALOG Eisai R&D Management Co., Ltd. (JP) 2020-04-29 EP disclosed
EP-1334111-A2 PHOSPHINOAMIDITE CARBOXYLATES AND ANALOGS THEREOF IN THE SYNTHESIS OF OLIGONUCLEOTIDES HAVING REDUCED INTERNUCLEOTIDE CHARGE Dellinger, Douglas J. (US) 2003-08-13 EP disclosed
WO-2002032912-A2 PHOSPHINOAMIDITE CARBOXYLATES AND ANALOGS THEREOF IN THE SYNTHESIS OF OLIGONUCLEOTIDES HAVING REDUCED INTERNUCLEOTIDE CHARGE DELLINGER DOUGLAS J (US) 2002-04-25 WO disclosed
EP-0934330-A1 BASE-PROTECTED NUCLEOTIDE ANALOGS WITH PROTECTED THIOL GROUPS Hanna, Michelle M. (US) 1999-08-11 EP disclosed
WO-1998003532-A9 BASE-PROTECTED NUCLEOTIDE ANALOGS WITH PROTECTED THIOL GROUPS 1998-05-28 WO disclosed
WO-1998003532-A1 BASE-PROTECTED NUCLEOTIDE ANALOGS WITH PROTECTED THIOL GROUPS HANNA MICHELLE M (US) 1998-01-29 WO disclosed
EP-0689460-A1 CYCLOBUTYL ANTISENSE OLIGONUCLEOTIDES, METHODS OF MAKING AND USE THEREOF ISIS PHARMACEUTICALS, INC. (US) 1996-01-03 EP disclosed
WO-1994001445-A1 BASE-PROTECTED NUCLEOTIDE ANALOGS WITH PROTECTED THIOL GROUPS RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1994-01-20 WO disclosed
EP-0136693-A2 Production of cytidine derivatives Takeda Chemical Industries, Ltd. (JP) 1985-04-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200216488-A1 MODIFIED NUCLEIC ACID MONOMER COMPOUND AND OLIGONUCLEIC ACID ANALOG POLRMT, DERA, PCNA ELANE 949/4885FGFR1 2050/4885LMNA 573/4885
US-11208429-B2 Modified nucleic acid monomer compound and oligonucleic acid analog POLRMT, DERA, PCNA ELANE 949/4885FGFR1 2050/4885LMNA 573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.